What Makes Trans-indolyl-3-acryloylglycine Identified by High-performance Liquid Chromatography Relevant to Pervasive Developmental Disorders?

Journal of Nutritional and Environmental Medicine

Volumn 13, Issue 4, 2003, Pages 231-237

  Whiteley, Paul ^a   Shattock, Paul ^a  

^a UNIVERSITY OF SUNDERLAND   (United Kingdom)

Author keywords

High performance liquid chromatography; Pervasive developmental disorder; Trans indolyl 3 acryloylglycine

Indexed keywords

GLYCINE DERIVATIVE; INDOLYL 3 ACRYLOYLGLYCINE; UNCLASSIFIED DRUG;

ARTICLE; ASPERGER SYNDROME; AUTISM; CHILD; COMORBIDITY; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; DRUG UTILIZATION; ELECTRONICS; ELUTION; EPILEPSY; FEMALE; FISHER EXACT TEST; HEALTH STATUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PATIENT; PREVALENCE; PRIORITY JOURNAL; SAMPLE; URINALYSIS; URINE;

MARTES PENNANTI;

EID: 1642537666     PISSN: 13590847     EISSN: None     Source Type: Journal    
DOI: 10.1080/13590840310001641996     Document Type: Article

References (20)

1. Kanner L. Autistic disturbances of affective contact. Nervous Children 1943; 2: 217-50.
2. Asperger H. Die 'autistischen Psychopathen' im Kindesalter. Arch Psych Nerv 1944; 117: 76-136.
3. Shattock P, Whiteley P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets 2002; 6: 175-83.
4. Knivsberg AM, Reichelt KL, Nødland M. Reports on dietary intervention in autistic disorders. Nutr Neurosci 2001; 4: 25-37.
5. Wakefield AJ, Murch SH, Anthony A et al. Ileal-nodular hyperplasia. Non-specific colitis and pervasive developmental disorder in children. Lancet 1998; 351: 637-41.
6. Wakefield AJ, Anthony A, Murch SH et al. Enterocolitis in children with developmental disorders. Am J Gastroenterol 2000; 95: 2285-95.
7. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in "low-functioning" autistic children: a pilot study. Biol Psychiatr 1999; 46: 420-4.
8. Furlano RI, Anthony A, Day R et al. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J Pediatr 2001; 138: 366-72.
9. Sandler RH, Finegold SM, Bolte ER et al. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol 2000; 15: 429-35.
10. Reichelt KL, Hole K, Hamberger A et al. Biologically active peptide containing fractions in schizophrenia and childhood autism. Adv Bio Psychopharm 1981; 28: 627-43.
11. Shattock PEG, Kennedy A, Rowell F, Berney TP. The role of neuropeptides in autism and their relationship with classical neurotransmitters. Brain Dysfunct 1990; 3: 328-45.
12. Anderson RJ, Bendell DJ, Garnett I et al. Identification of indolyl-3-acryloylglycine in the urine of people with autism. J Pharm Pharmacol 2002; 54: 295-8.
13. Mills MJ, Savery D, Shattock PEG. Rapid analysis of low levels of indolyl-3-acryloylglycine in human urine by high-performance liquid chromatography. J Chromatogr B 1998; 712: 51-8.
14. Whiteley P, Rodgers J, Savery D, Shattock P. A gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism 1999; 3: 45-65.
15. Hooper M. IAG, a marker molecule for dietary intervention in overlapping syndromes. Nutr Practitioner 2000; 2: 35-6.
16. Whiteley P. Developmental, behavioural and somatic factors in pervasive developmental disorders: preliminary analysis. Child: Care, Health Dev, in press.
17. Marklova E, Malina L, Hais IM. Urinary excretion of indolyl-3- acryloylglycine in some skin affections. Clin Chim Acta 1975; 64: 273-80.
18. Giovanardi Rossi P, Posar A, Parmeggiani A. Epilepsy in adolescents and young adults with autistic disorder. Brain Develop 2000; 22: 102-6.
19. Schutz H, Feldmann KF, Faigle JW, Kriemler HP, Winkler T. The metabolism of 14C-oxcarbazepine in man. Xenobiotica 1986; 16: 769-78.
20. th International Durham Conference, 10-12 April 2002, Durham, UK. Autism Research Unit, UK.